title: Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study.
abstract: OBJECTIVE
  To determine the role of oseltamivir prophylaxis for immunocompromised patients.
  
  
  METHODS
  Prospective, non-blinded, non-controlled observational study.
  
  
  METHODS
  A paediatric cancer centre, Hong Kong.
  
  
  METHODS
  Thirty-two patients, immunocompromised by chemotherapy or bone marrow transplantation during an influenza season in 2001.
  
  
  METHODS
  Oral oseltamivir prophylaxis 75 mg/d for 8 weeks.
  
  
  METHODS
  Laboratory-confirmed influenza infection, symptoms of influenza, drug compliance, and any side-effects from oseltamivir treatment. Laboratory monitoring included virological surveillance for influenza A and B, blood counts, and renal and liver function tests.
  
  
  RESULTS
  Patients' median age was 14.3 years (range, 6.3-23.4 years). Underlying conditions included malignancy (n=29) and other haematological diseases (n=3). No documented influenza infection according to serological tests was present throughout the study period. Five patients with symptoms of upper respiratory tract infection did not have any influenza infection detected by rapid virological assay and viral culture. For 16% of patients, the main side-effect in the study was gastro-intestinal upset.
  
  
  CONCLUSIONS
  Oral oseltamivir 75 mg once daily for 8 weeks may be useful in the prevention of influenza infection in patients immunocompromised by chemoradiotherapy; side-effects are few and acceptable.
authors.affiliation: Department of Paediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. kiwai-chik@cuhk.edu.hk
authors.forename: K W
authors.initials: KW
authors.lastname: Chik
authors.forename: C K
authors.initials: CK
authors.lastname: Li
authors.forename: P K S
authors.initials: PK
authors.lastname: Chan
authors.forename: M M K
authors.initials: MM
authors.lastname: Shing
authors.forename: V
authors.initials: V
authors.lastname: Lee
authors.forename: J S L
authors.initials: JS
authors.lastname: Tam
authors.forename: P M P
authors.initials: PM
authors.lastname: Yuen
mesh_terms: D000081:Acetamides / Q000008:administration & dosage*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006723:Hong Kong; D006776:Hospitals, Pediatric; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D007251:Influenza, Human / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D009369:Neoplasms / Q000175:diagnosis / Q000276:immunology*; D016522:Oncology Service, Hospital; D053139:Oseltamivir; D011446:Prospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000081:Acetamides; D000998:Antiviral Agents; D053139:Oseltamivir